Rituximab in combination with multiagent chemotherapy for Pediatric follicular lymphoma

Riten Kumar, Paul J. Galardy, Ahmet Dogan, Vilmarie Rodriguez, Shakila P. Khan

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Given the rarity of follicular lymphoma (FL) in children, there is limited data on which to base treatment recommendations. Herein, we report our institutional experience of using rituximab with multiagent chemotherapy for pediatric FL. Six pediatric patients were diagnosed with FL from 2000 to 2009. All patients received rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for varying durations. Five of the six patients remain in remission with a median follow-up of 31 months. Larger randomized trials are indicated to establish the efficacy of this regimen for pediatric FL patients.

Original languageEnglish (US)
Pages (from-to)317-320
Number of pages4
JournalPediatric Blood and Cancer
Issue number2
StatePublished - Aug 2011


  • Follicular lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Dive into the research topics of 'Rituximab in combination with multiagent chemotherapy for Pediatric follicular lymphoma'. Together they form a unique fingerprint.

Cite this